Therion to close, sell assets after cancer drug trial fails
Therion Biologics Corp. , a 15-year-old Cambridge company trying to develop a new breed of vaccines to fight cancer, will be shuttered and sold after its most promising drug candidate failed a pivotal human test, the company's chief executive said yesterday. (Full article: 635 words)
This article is available in our archives:
Globe Subscribers
FREE for subscribers
Subscribers to the Boston Globe get unlimited access to our archives.
Not a subscriber?
Non-Subscribers
Purchase an electronic copy of the full article. Learn More
- $4.95 1 article
- $9.95 4 articles
- $25.95 Monthly
